ZLAB N logo

Zai Lab LimitedBMV:ZLAB N Stock Report

Market Cap Mex$65.0b
Share Price
Mex$810.00
My Fair Value
n/a
1Yn/a
7D0%
Portfolio Value
​
View

Zai Lab Limited

BMV:ZLAB N Stock Report

Market Cap: Mex$65.0b

Zai Lab (ZLAB N) Stock Overview

A biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases. More details

ZLAB N fundamental analysis
Snowflake Score
Valuation4/6
Future Growth5/6
Past Performance0/6
Financial Health4/6
Dividends0/6

Rewards

Trading at 63.1% below our estimate of its fair value

Earnings are forecast to grow 68.61% per year

Earnings have grown 9.1% per year over the past 5 years

Risk Analysis

Shares are highly illiquid


ZLAB N Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View Stock Community

Zai Lab Limited Competitors

Price History & Performance

Summary of share price highs, lows and changes for Zai Lab
Historical stock prices
Current Share PriceUS$810.00
52 Week HighUS$810.00
52 Week LowUS$560.00
Beta1.03
1 Month Change0%
3 Month Changen/a
1 Year Changen/a
3 Year Change-11.34%
5 Year Changen/a
Change since IPO-45.27%

Recent News & Updates

Recent updates

Shareholder Returns

ZLAB NMX BiotechsMX Market
7D0%0%0%
1Yn/a0%0%

Return vs Industry: Insufficient data to determine how ZLAB N performed against the MX Biotechs industry.

Return vs Market: Insufficient data to determine how ZLAB N performed against the MX Market.

Price Volatility

Is ZLAB N's price volatile compared to industry and market?
ZLAB N volatility
ZLAB N Average Weekly Movementn/a
Biotechs Industry Average Movement0%
Market Average Movement0%
10% most volatile stocks in MX Market0%
10% least volatile stocks in MX Market0%

Stable Share Price: ZLAB N's share price has been volatile over the past 3 months compared to the MX market.

Volatility Over Time: Insufficient data to determine ZLAB N's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
20131,869Samantha Duwww.zailaboratory.com

Zai Lab Limited, a biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases. Its commercial products include Zejula, an orally administered poly (ADP-ribose) polymerase 1/2 inhibitor for treating ovarian cancer; VYVGART, a human IgG1 antibody fragment for generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy; NUZYRA for community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections; Optune for glioblastoma multiforme; Qinlock for gastrointestinal stromal tumors; Xacduro for treating hospital-acquired and ventilator-associated bacterial pneumonia caused by a cinetobacter baumannii-calcoaceticus complex; and Augtyro for the treatment of ROS proto-oncogene 1 and non-small cell lung cancer. The company’s oncology pipeline includes bemarituzumab, tumor treating fields, tisotumab vedotin, and repotrectinib; and immunology, neuroscience, and infectious disease pipeline comprises efgartigimod and xanomeline and trospium chloride.

Zai Lab Limited Fundamentals Summary

How do Zai Lab's earnings and revenue compare to its market cap?
ZLAB N fundamental statistics
Market capMex$64.99b
Earnings (TTM)-Mex$3.96b
Revenue (TTM)Mex$7.97b
8.1x
P/S Ratio
-16.4x
P/E Ratio

Is ZLAB N overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ZLAB N income statement (TTM)
RevenueUS$427.80m
Cost of RevenueUS$390.45m
Gross ProfitUS$37.35m
Other ExpensesUS$249.87m
Earnings-US$212.52m

Last Reported Earnings

Jun 30, 2025

Next Earnings Date

n/a

Earnings per share (EPS)-1.91
Gross Margin8.73%
Net Profit Margin-49.68%
Debt/Equity Ratio22.0%

How did ZLAB N perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/09/09 11:50
End of Day Share Price 2025/06/12 00:00
Earnings2025/06/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Zai Lab Limited is covered by 30 analysts. 16 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Bo LiBofA Global Research
Louise ChenCantor Fitzgerald & Co.
Li Wang WatsekCantor Fitzgerald & Co.